Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category

Thriving at the Survival Calls during Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL

Author and Curator: Aviva Lev-Ari, PhD, RN


The source for the inspiration to write this curation is described in

Survival Calls during Careers in the Digital Age


In this curation, I present the following concepts in three parts:

  1. Part 1: Authenticity of Careers in the Digital Age: In Focus, the BioTechnology Sector
  2. Part 2: Top 10 books to help you survive the Digital Age

  3. Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76 


Part 1: Authenticity of Careers in the Digital Age: 

In Focus, the BioTechnology Sector


Lisa LaMotta, Senior Editor, BioPharma Dive wrote in Conference edition | June 11, 2018

Unlike that little cancer conference in Chicago last week, the BIO International convention is not about data, but about the people who make up the biopharma industry.

The meeting brings together scientists, board members, business development heads and salespeople, from the smallest virtual biotechs to the largest of pharmas. It allows executives at fledgling biotechs to sit at the same tables as major decision-makers in the industry — even if it does look a little bit like speed dating.

But it’s not just a partnering meeting.

This year’s BIO also sought to shine a light on pressing issues facing the industry. Among those tackled included elevating the discussion on gender diversity and how to bring more women to the board level; raising awareness around suicide and the need for more mental health treatments; giving a voice to patient advocacy groups; and highlighting the need for access to treatments in developing nations.

Four days of meetings and panel discussions are unlikely to move the needle for many of these challenges, but debate can be the first step toward progress.

I attended the meetings on June 4,5,6, 2018 and covered in Real Time the sessions I attended. On the link below, Tweets, Re-Tweets and Likes mirrors the feelings and the opinions of the attendees as expressed in real time using the platform. This BioTechnology events manifested the AUTHENTICITY of Careers in the Digital Age – An AGE like no Other, also known as, DIGITAL.

The entire event is covered on by the following hash tag and two handles:


I covered the events on two tracks via two Twitter handles, each handle has its own followers:

The official LPBI Group account

The Aviva Lev-Ari, PhD, RN account

Track A:

  • Original Tweets by @Pharma_BI and by @AVIVA1950 for #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN


  • Reactions to Original Tweets by @Pharma_BI and by @AVIVA1950 from #BIO2018

Curator: Aviva Lev-Ari, PhD, RN

Track B:

  • Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN

Part 2: Top 10 books to help you survive the digital age

From Philip K Dick’s obtuse robots to Mark O’Connell’s guide to transhumanism, novelist Julian Gough picks essential reading for a helter skelter world

Here are 10 of the books that did help me [novelist Julian Gough]: they might also help you understand, and survive, our complicated, stressful, digital age.

  1. Marshall McLuhan Unbound by Marshall McLuhan (2005)
    The visionary Canadian media analyst predicted the internet, and coined the phrase the Global Village, in the early 1960s. His dense, complex, intriguing books explore how changes in technology change us. This book presents his most important essays as 20 slim pamphlets in a handsome, profoundly physical, defiantly non-digital slipcase.
  2. Ubik by Philip K Dick (1969)
    Pure pulp SF pleasure; a deep book disguised as a dumb one. Dick shows us, not a dystopia, but a believably shabby, amusingly human future. The everyman hero, Joe Chip, wakes up and argues with his robot toaster, which refuses to toast until he sticks a coin in the slot. Joe can’t do this, because he’s broke. He then has a stand-up row with his robot front door, which won’t open, because he owes it money too … Technology changes: being human, and broke, doesn’t. Warning: Dick wrote Ubik at speed, on speed. But embedded in the pulpy prose are diamonds of imagery that will stay with you for ever.
  3. The Singularity Is Near by Ray Kurzweil (2005)
    This book is what Silicon Valley has instead of a bible. It’s a visionary work that predicts a technological transformation of the world in our lifetime. Kurzweil argues that computer intelligence will soon outperform human thought. We will then encode our minds, upload them, and become one with our technology, achieving the Singularity. At which point, the curve of technological progress starts to go straight up. Ultimately – omnipotent, no longer mortal, no longer flesh – we transform all the matter in the universe into consciousness; into us.
  4. To Be a Machine by Mark O’Connell (2017)
    This response to Kurzweil won this year’s Wellcome prize. It’s a short, punchy tour of transhumanism: the attempt to meld our minds with machines, to transcend biology and escape death. He meets some of the main players, and many on the fringes, and listens to them, quizzically. It is a deliberately, defiantly human book, operating in that very modern zone between sarcasm and irony, where humans thrive and computers crash.
  5. A Visit from the Goon Squad by Jennifer Egan (2011)
    This intricately structured, incredibly clever novel moves from the 60s right through to a future maybe 15 years from now. It steps so lightly into that future you hardly notice the transition. It has sex and drugs and rock’n’roll, solar farms, social media scams and a stunningly moving chapter written as a PowerPoint presentation. It’s a masterpiece. Life will be like this.
  6. What Technology Wants by Kevin Kelly (2010)
    Kelly argues that we scruffy biological humans are no longer driving technological progress. Instead, the technium, “the greater, global, massively interconnected system of technology vibrating around us”, is now driving its own progress, faster and faster, and we are just caught up in its slipstream. As we accelerate down the technological waterslide, there is no stopping now … Kelly’s vision of the future is scary, but it’s fun, and there is still a place for us in it.
  7. The Meme Machine by Susan Blackmore (1999)
    Blackmore expands powerfully and convincingly on Richard Dawkins’s original concept of the meme. She makes a forceful case that technology, religion, fashion, art and even our personalities are made of memes – ideas that replicate, mutate and thus evolve over time. We are their replicators (if you buy my novel, you’ve replicated its memes); but memes drive our behaviour just as we drive theirs. It’s a fascinating book that will flip your world upside down.
  8. Neuromancer by William Gibson (1984)
    In the early 1980s, Gibson watched kids leaning into the screens as they played arcade games. They wanted to be inside the machines, he realised, and they preferred the games to reality. In this novel, Gibson invented the term cyberspace; sparked the cyberpunk movement (to his chagrin); and vividly imagined the jittery, multi-screened, anxious, technological reality that his book would help call into being.
  9. You Are Not a Gadget: A Manifesto by Jaron Lanier (2010)
    Lanier, an intense, brilliant, dreadlocked artist, musician and computer scientist, helped to develop virtual reality. His influential essay Digital Maoism described early the downsides of online collective action. And he is deeply aware that design choices made by (mainly white, young, male) software engineers can shape human behaviour globally. He argues, urgently, that we need to question those choices, now, because once they are locked in, all of humanity must move along those tracks, and we may not like where they take us. Events since 2010 have proved him right. His manifesto is a passionate argument in favour of the individual voice, the individual gesture.
  10. All About Love: New Visions by bell hooks (2000)
    Not, perhaps, an immediately obvious influence on a near-future techno-thriller in which military drones chase a woman and her son through Las Vegas. But hooks’s magnificent exploration and celebration of love, first published 18 years ago, will be far more useful to us, in our alienated digital future, than the 10,000 books of technobabble published this year. All About Love is an intensely practical roadmap, from where we are now to where we could be. When Naomi and Colt find themselves on the run through a militarised American wilderness of spirit, when GPS fails them, bell hooks is their secret guide.


Part 3: A case study on Thriving at the Survival Calls during Careers in the Digital Age:  Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76


On June 10, 2018


Following, is a case study about an alumna of HUJI and UC, Berkeley as an inspirational role model. An alumna’s profile in context of dynamic careers in the digital age. It has great timeliness and relevance to graduate students, PhD level at UC Berkeley and beyond, to all other top tier universities in the US and Europe. As presented in the following curations:

Professional Self Re-Invention: From Academia to Industry – Opportunities for PhDs in the Business Sector of the Economy


Pioneering implementations of analytics to business decision making: contributions to domain knowledge conceptualization, research design, methodology development, data modeling and statistical data analysis: Aviva Lev-Ari, UCB, PhD’83; HUJI, MA’76


This alumna is Editor-in-Chief of a Journal that has other 173 articles on Scientist: Career Considerations


In a 5/22/2018 article, Ways to Pursue Science Careers in Business After a PhD by Ankita Gurao,

Unemployment figures of PhDs by field of science are included, Ankita Gurao identifies the following four alternative careers for PhDs in the non-academic world:

  1. Science Writer/Journalist/Communicator
  2. Science Management
  3. Science Administration
  4. Science Entrepreneurship

My career, as presented in Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

has the following phases:

  • Phase 1: Research, 1973 – 1983
  • Phase 2: Corporate Applied Research in the US, 1985 – 2005
  • Phase 3: Career Reinvention in Health Care, 2005 – 2012
  • Phase 4: Electronic Scientific Publishing, 4/2012 to present

These four phases are easily mapped to the four alternative careers for PhDs in the non-academic world. One can draw parallel lines between the four career opportunities A,B,C,D, above, and each one of the four phases in my own career.

Namely, I have identified A,B,C,D as early as 1985, and pursued each of them in several institutional settings, as follows:

A. Science Writer/Journalist/Communicator – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present 

B. Science Management – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005 and Phase 3: Career Reinvention in Health Care, 2005 – 2012 

C. Science Administration – see link above for Phase 2: Corporate Applied Research in the US, 1985 – 2005and Phase 4: Electronic Scientific Publishing, 4/2012 to present 

D. Science Entrepreneurship – see link above for Phase 4: Electronic Scientific Publishing, 4/2012 to present  

Impressions of My Days at Berkeley in Recollections: Part 1 and 2, below.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 –About my doctoral advisor, Allan Pred, other professors and other peers

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

The topic of Careers in the Digital Age is closely related to my profile, see chiefly: Four-phase Career, Reflections, Recollections Parts 1 & 2 and information from other biographical sources, below.

Other sources for my biography



Read Full Post »

  1. ⁩ ⁦⁩ in Cambridge study sensors on patients contact dermatitis patients sensors monitor movement text mining sensation reported by patients with sensors trajectory monitored drug device external partnership

  2. ⁩ ⁦ new drug: Biotech in Scripps, CA and another in Cambridge, MA and ⁦⁩ as Pharma collaboration with biotech Partnership with UPenn with Duke, NC agility in small co scale in Pharma

  3. ⁩ ⁦ and Medical community decide on directions for surrogate followed by survival NASH redefine NEW drug innovations will move faster Vaccine for NASH growing obesity population Network for collaboration

  4. ⁩ immunicity correlated confirm benefit in based study patient to benefit early on while cost benefit be known later inflammatory indicators across diseases JAKS inhibitors which drug for which patient

  5. ⁩ ⁦⁩ redefine by genomics clinical trials on patients with Gene expression 150 patients 60% improve rate new drug approved in 2011 in oncology how sustain innovation by cost effective trials? Patient selection

  6. Mikael Dolsten R&D budget for contribution capital allocation focus on deep expertise in multiple drugs in multiple indications Lipitor dependence ends patent expiration

  7. only by knowing both one can develop applications in vs questions are the hard part vs expertise needed for structural models type of data collected may not be best

  8. for idiopathic fibrosis using CONNECTION OF DRUG AND DISEASE known after development, pharma needs that BEFORE a drug is developed, clinics based on BRCA for treatment, finding binding targets/drug

  9. for patients goals apply right approach to care right drug respond to therapy is a HC goal combined with patient goals

  10. @FoundationMedicine in 7 days genomic data, clinical data and patient of patient took place in clean data sets are a must for patient total clinical profile

  11. COHORT is assisted by for clinical trials of rare types of cancers on small population of patients. Synthetic data compared with observed data for can get wrong results by using

  12. @FoundationMedicine sequenced 200,000 Cancer patients genome use data to Target positive predicted responders to accelerate clinical trials. use of on genomic data for

  13. @KatrineBosley @EditasMedicine Valuation for 23andme? Each pool of capital has different investors been attracted

  14. @JohnMaraganore @ALNYLAMPHARMACEUTICALS In 16 years rained $4Billion and expenses $2.5Billion – still not profitable – that what it takes

  15. @JeanFrancisFormela Science is extraordinary A lot of capital and very many tech ventures over supply of capital accelerates the business More capital is better, what to invest is critical

  16. US is not the only player, CANADA’ universal payer system made major strides lung cancer experienced development of 50 drug base on tumor type predict likelihood drug resistance BR CA patient which not require therapy

  17. @RajuKucherlapati Integration of EMR Partners leader missing link is integration of Genomic dat aat the patient level with clinical dat of patients Patients will manage their 23andme data PM is global vs access to care

  18. @RajuKucherlapati with million of people with genetic and medical information — searches of profile too group patients for optimal of with DB of – IBM

  19. @RajuKucherlapati Detection at pre-natal stages of multiple fetal disorders, abnormality, diagnosis drive treatment – genetic testing critical in cost Cardiomayopaty: in Young athlete genetic disorder

  20. Sajeev Kohli (11th Grade, Waterloo, On, Canada)Receives Top Honor at International BioGENEius Challenge Students from California, Washington and Germany named runners-up June 5, 2018 – Boston, Massachusetts –

  21. @TimothyBelski Joint Program Executive Office for Chemical and Biological Defense Manufacturing for DoD Infrastructure to manage across Government RFP Process

  22. We cover this event in Real Time

  23. Aviva Lev-Ari Retweeted MassBio

    BRAVO MA the of

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted JNJ Innovation

    Interested Chief Scientific Officer

    Aviva Lev-Ari added,

Read Full Post »

Re-Tweets and Likes by @Pharma_BI and by @AVIVA1950 from #BIO2018 @IAmBiotech @BIOConvention – BIO 2018, Boston, June 4-7, 2018, BCEC

Curator: Aviva Lev-Ari, PhD, RN


  1.   Retweeted

    Aviva Lev-Ari Retweeted Jeff Galvin

    Well put I agree with you, Jeff

    Aviva Lev-Ari added,

  2.   Retweeted

    Aviva Lev-Ari Retweeted I Am Biotech

    Aviva Lev-Ari added,

  3. Aviva Lev-Ari Retweeted Christiane Truelove

    BRAVO FDA in 2018 is AGILE

    Aviva Lev-Ari added,

  4. Aviva Lev-Ari Retweeted CCAB

    ASCO weigh in on CAR-Ts versus bispecific antibodies

    Aviva Lev-Ari added,

  5. Aviva Lev-Ari Retweeted Dana-Farber News

    Aviva Lev-Ari added,

  6. Aviva Lev-Ari Retweeted Jim Greenwood

    BRAVO inaugural Henri A. Termeer Biotechnology Visionary Award

    Aviva Lev-Ari added,

  7. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  8.   Retweeted

    The 2018 Bio International Convention has been amazing! This was the view from our water taxi ride to the hotel last night! 🚤🛳🛥⛵️

  9. Aviva Lev-Ari Retweeted Ozmosi

    Aviva Lev-Ari added,

  10. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi

    Aviva Lev-Ari added,

  11. Aviva Lev-Ari Retweeted Sue Desmond-Hellmann

    HEROS for cure

    Aviva Lev-Ari added,

  12. Aviva Lev-Ari Retweeted BIO Intl Convention

    Aviva Lev-Ari added,

  13. Aviva Lev-Ari Retweeted Noy Kaufman

    Aviva Lev-Ari added,

  14. Aviva Lev-Ari Retweeted Business Sweden Invest

    Aviva Lev-Ari added,

  15. Aviva Lev-Ari Retweeted Alaric DeArment

    Aviva Lev-Ari added,

  16. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  17. Aviva Lev-Ari Retweeted JNJ Innovation

    Aviva Lev-Ari added,

  18. Aviva Lev-Ari Retweeted Elizabeth Cutler

    Aviva Lev-Ari added,

  19. Aviva Lev-Ari Retweeted Sanofi US

    BRAVO Sanofi, so smart to have bought Genzyme

    Aviva Lev-Ari added,

  20. Aviva Lev-Ari Retweeted Biotech Institute

    BRAVO Challenge!

    Aviva Lev-Ari added,

  21. Aviva Lev-Ari Retweeted IAM Platform

    Aviva Lev-Ari added,

  22. Aviva Lev-Ari Retweeted Sema4

    Aviva Lev-Ari added,

  23. Aviva Lev-Ari Retweeted Worldwide Clinical

    Aviva Lev-Ari added,

  24. Aviva Lev-Ari Retweeted Lori Collins

    ‘Largest Business Partnering Event’! Proud to cover the event in

    Aviva Lev-Ari added,

  25. Aviva Lev-Ari Retweeted Mike Huckman

    Aviva Lev-Ari added,

  26. Aviva Lev-Ari Retweeted Cleveland Scott York

    45,000 Partening sessions – BRAVO !!

    Aviva Lev-Ari added,

  27. Aviva Lev-Ari Retweeted Thermo Fisher G.R.

    Aviva Lev-Ari added,

  28. Aviva Lev-Ari Retweeted The Global IP Center

    Aviva Lev-Ari added,

  29. Aviva Lev-Ari Retweeted NHS Research Scotland

    BRAVO Scotland in

    Aviva Lev-Ari added,

  30. Aviva Lev-Ari Retweeted Quanterix

    BRAVO landscape in in light of

    Aviva Lev-Ari added,

  31. Aviva Lev-Ari Retweeted Vanitha Sekar

    made by Bill & Melinda Gates Medical Research Institution most nobel cause

    Aviva Lev-Ari added,

  32. Aviva Lev-Ari Retweeted HLC

    in Medicine

    Aviva Lev-Ari added,

  33. Aviva Lev-Ari Retweeted BlueCloud

    BRAVO Argentine

    Aviva Lev-Ari added,

  34. Aviva Lev-Ari Retweeted NFIA North America

    BRAVO Holland! places Holland No. 1 in the world for medical technology patents!

    Aviva Lev-Ari added,

  35. Aviva Lev-Ari Retweeted Intract Pharma

    Amazing COnference

    Aviva Lev-Ari added,

  36. Aviva Lev-Ari Retweeted MacBioCom

    Aviva Lev-Ari added,

  37. Aviva Lev-Ari Retweeted Hassan Naqvi

    meets INDUSTRY: BIOTECH & PHARMA with success

    Aviva Lev-Ari added,

  38. Aviva Lev-Ari Retweeted IN-PART

    INDEED, the best conference I have attended since 2013 when I cover in Real Time conferences as

    Aviva Lev-Ari added,

  39. Aviva Lev-Ari Retweeted JNJ Innovation

    BRAVO J&J for your broad spectrum in

    Aviva Lev-Ari added,

  40. Aviva Lev-Ari Retweeted Penny Heaton

    MOST NOBEL cause by MRI can be a catalyst to address urgent global health

    Aviva Lev-Ari added,

  41. Aviva Lev-Ari Retweeted I Am Biotech

    bRAVO I Am Biotech

    Aviva Lev-Ari added,

  42. Aviva Lev-Ari Retweeted ARMI

    BRAVO Aussi

    Aviva Lev-Ari added,

  43.   Retweeted

    Fireside chat with at

  44.   Retweeted

    Jeff Galvin, CEO of Rockville-based presented his company’s innovations in therapies for HIV, phenylketonuria, and cancer at . After the presentation, he was mobbed by potential investors and partners!

  45.   Retweeted

    How do you schedule hundreds of meetings all at once? has it figured out. Meeting many great potential supporters.

  46.   Retweeted

    It doesn’t get more epic than this l! The QUEEN, DIANA ROSS!

  47.   Retweeted

    Absolutely inspiring group of advocates on the patient voice panel. I feel honored to be in the room with them, listening to their remarkable stories and insights.

  48.   Retweeted

    Board of Directors Chair on diversity in during his Fireside Chat

  49.   Retweeted

    And for more on-the-ground analysis while you’re at , sign up for our daily newsletter, BIO in 30 Seconds.

  50.   Retweeted

    THURSDAY: (yes, twice!), 9:00am, 259B, on biotech’s data tsunami

  51.   Retweeted

    TUESDAY: , 4:15pm, 259A, on a new era of biotech journalism

  52.   Retweeted

    TUESDAY: , 1:45pm, 210B, on how to apply the lessons of immunotherapy from cancer to other diseases.

  53.   Retweeted

    MONDAY: , 4:00pm, 210A, talking how to cut waste between big pharma and payers in precision medicine.

  54.   Retweeted

    MONDAY: , 1:00pm, 206AB, talking what drug hunters look for in early stage assets.

  55.   Retweeted

    MONDAY: , 12:30pm at , talking best practices for co-working in the life sciences. (From the archives)

  56.   Retweeted

    THREAD: STAT is all over . Here’s where to find us.

  57.   Retweeted

    speaking with the member delegation at We’ve come to share with the world the excellence of our life science community in Canada.

  58.   Retweeted

    Team Queensland ready to showcase our state’s fantastic capabilities in all things biotech in Boston

  59.   Retweeted

    kicks off tomorrow in Boston, MA. Dr Glenn Begley, CEO and Linda Peterson, COO will be attending. DM us if you would like to connect with them.

  60.   Retweeted

    Heading to my first BIO convention, the rain can’t stop my excitement! 😁

  61.   Retweeted

    Proud to sponsor . We at love supporting and their missions to improve our health! See you at as we keep the startup celebration going tomorrow night! BIOGA25 for $25 GA tix

  62.   Retweeted

    Our friends at have put together the ultimate guide to the (). It features a complete list of conferences, private events/receptions, plus much more, all happening throughout the week. Get it here >>

  63.   Retweeted

    Through Pfizer Ventures, we plan to invest $600M in innovative science, with approximately $150M specifically targeted toward neuroscience. Join us at to learn more:

  64.   Retweeted

    “It will take you 10-15 years to get a breakthrough, but if you don’t start, you’ll never get there,” says J&J’s CSO Paul Stoffels when asked about at – at Boston Convention & Exhibition Center

  65.   Retweeted
  66.   Retweeted

    Great Q on driving (innovation in) “Huge opportunity in partnering with Pharma, not in replacing them, mainly due to the complexity of

  67.   Retweeted

    Penny Heaton Retweeted BIO Intl Convention

    Looking forward to next week, where we’ll have the opportunity to formally introduce the Gates MRI and share the mission, vision, and values behind the work we’re doing to accelerate product development for diseases that disproportionately affect the world’s poorest.

    Penny Heaton added,

  68.   Retweeted

    Attending ? These SECRET STAIRS, only minutes from the convention center, lead to our local Fort Point restos, breweries and more!

  69.   Retweeted

    At … it’s like Epcot in here! So many countries and states courting the bio biz.

  70.   Retweeted

    the best way to conclude this incredible !!!

  71.   Retweeted

    Making History in Boston.

  72.   Retweeted

    At biggest biopharma partnering event in the world, scale is pretty amazing…

  73.   Retweeted

    I can’t believe attendees are told by conference organizers that “locals” recommend: “Let loose and explore the nightlife of Boston, grab a couple beers at the iconic “Cheers” bar.” Let me qualify that: NOBODY IN THIS CITY WOULD RECOMMEND THAT.

  74.   Retweeted

    How cool is this new tool from ?! It provides info on partnering opportunities and contacts for over 60+ patient advocacy groups. Very useful!

  75.   Retweeted

    And here it is, the most famous Paul Stoffels quote we hear ALL THE TIME at “You take the risk and I take the blame” in

  76.   Retweeted


  77.   Retweeted

    . – tonight, Karl-Rudolf Erlemann of was all of us.

  78.   Retweeted

    Which biopharmaceutical companies are making a real difference for patients? Our CSO Michael Severino explains how to spot R&D leaders.

  79.   Retweeted

    Had to get to the front row for the encore at live!

  80.   Retweeted

    There is till time to visit us at , booth 1344. If you require nucleosides and carbohydrates for your business, come to speak to our specialist – maybe we can help.

  81.   Retweeted

    Thank you and for helping me meet a real life superhero. Ashanti DeSilva the first person in the world treated with 28 years ago. A passionate , advocate and a personal inspiration

  82.   Retweeted

    Wonderful to meet Baroness Fairhead CBE, Minister of State at DIT on the UK Pavilion at

  83.   Retweeted

    The expo floor is a trip around the world of innovation!

  84.   Retweeted

    Great reception at Startup Stadium today. It’s been a great week here in Boston.

  85.   Retweeted

    No rest for attendees! It’s the last day of Convention, but the action isn’t slowing down yet. Look out for these featured events in today’s schedule:

  86.   Retweeted

    It was another history-making ! We look forward to hosting you in on 2019 to make even more history!

  87.   Retweeted

    Pitt has once again surpassed its records for startups in fiscal 2019 with 21 companies spun out of the university. Could a Pitt startup be your next entrepreneurial or investment opportunity?

  88.   Retweeted

    I will survive! ⁦ very Darwinian!

  89.   Retweeted
    Replying to 

    No “jail” means being forced to listen to speak at . I hope he’s wearing cool socks.

  90.   Retweeted

    Don Seiffert Retweeted Suzanne Fraser

    Diana Ross performing “I Will Survive” at the Convention Center for

    Don Seiffert added,

  91.   Retweeted

    Agendia Retweeted PMC

    Thanks for inviting our CMO, Dr William Audeh, to join this important and timely in Action panel at

    Agendia added,

  92.   Retweeted

    Last day for and last chance to meet 10 companies from and health cluster. Visit us on booth 527, France pavilion.

  93.   Retweeted

    Still time to visit us at booth 1753

  94.   Retweeted

    Find and meet our BD Manager Emmanuelle Astoul who is attending in Boston to talk about collaboration opportunities with

  95.   Retweeted

    Today last day! Come visit us at booth #1328 and enjoy some argentinian alfajores and coffee!

  96.   Retweeted

    Today at 10:30am, join our Senior Investment Director, Dr. Karen Hong at for “Business Development & Finance: An Investor’s Perspective on Value of New Biotherapeutics” in Room 252AB, Level 2.

  97.   Retweeted

    Fun session y’day at on drug prices, R&D cost, and innovation – many thanks to & ! Good convo abt whether (a) competition will ⬇️ prices in cancer and rare dz, & (b) NIH, prizes, etc. can sustain & focus Rx innovation in the future.

  98.   Retweeted

    Speak to our Team on the UK Pavilion (stand 1333) at the Bio International Convention

  99.   Retweeted

    Want to learn more about collaboration between and JPEO-CBRND? Stop by booth 1913 to learn more and how Industry can engage with us.

  100.   Retweeted

    Home stretch! Day 4 begins with business development first thing in the morning. .

  101.   Retweeted

    Last day of kicks off with fireside chat in one hour

  102.   Retweeted

    At Shares the Journey: being an award-winning broadcast journalist and author, and a survivor of breast cancer and myelodysplastic syndrome (MDS),

  103.   Retweeted

    Over the past 21 years, we’ve forged long-term, mutually successful partnerships, bringing innovations and solutions together to meet the worlds healthcare needs. Connect with us at the Scottish Pavillion to discover what we can do for your clinical trial journey.

  104.   Retweeted

    ⁩ hosted a great alumni networking event around

  105.   Retweeted

    Rob Reiner and I will be joining you on stage shortly!

  106.   Retweeted

    Are you at ? Be sure to stop by Booth #2101 to learn more about the 10 remarkable Israeli companies, spanning the spectrum of ’s vigorous Life Sciences community- from innovative start-ups to established companies!

  107.   Retweeted

    Great discussion at today’s “Best Practices for Working with Patient Advocacy Organizations,” with our own Jessica Riviere, Senior Director, Biogen

  108.   Retweeted

    We are excited to have , CEO of with us live at the Massachusetts pavilion speaking live

  109.   Retweeted

    Our President of R&D Akshay Vaishnaw took the stage earlier today at the pavilion to tell our innovation and Massachusetts story. therapeutics

  110.   Retweeted

    Standing ovation for Ashanthi De Silva at ! “Have hope, be your own advocate, and never give up.” – at Boston Convention Center Grand Ballroom

  111.   Retweeted

    Diversity and inclusion is an BoD priority, an priority and my priority. During my fireside chat w/ Halozyme CEO Helen Torley today at , I committed to not participate in any future panel that is not diverse.

  112.   Retweeted

    Here in Massachusetts, innovation is a way of life. It truly is the . If you want it to happen, you need to be here – Massachusetts is the place where life sciences companies can find the people, the ideas and the resources they need to innovate and grow. – at Boston Convention & Exhibition Center

  113.   Retweeted

    We OFFICIALLY made history this week! BIO’s Joanne Duncan accepting our Guinness World Record for ‘Largest Business Parneting Event’

  114.   Retweeted

    Excited to hear member and Reg Affairs Committee member Kelli Tanzella of give her perspective on the regulatory paradigm for NGS panels.

  115.   Retweeted

    Trailblazing discoveries in health sciences are what we do here.

  116.   Retweeted

    Did you know that every 3.5 minutes someone will die from lung cancer? Boston University and investing in changing this

  117.   Retweeted

    We did it! We set a world record for the Largest Business Partnering Event. Thank you to everyone!

  118.   Retweeted

    I’ve been around the world twice. is the Epcot of Bio, Science & Pharma companies. Proud to see companies recognizing the Making great connections to support our students.

  119.   Retweeted

    Eager to elevate the & voice at this morning’s panel discussion on Communicating Value Through the Eye of the Beholder

  120.   Retweeted

    Need for evidence of PM’s value has emerged as & Dx Track” theme. Now, , , reps show / parallel review pathway, joint studies by commercial insurers/Dx companies will be key.

  121.   Retweeted

    The winner of Dr. Paul Janssen Award Jim Allison discusses the importance of elevating science to a household conversation if we want to improve our collective health.

  122.   Retweeted

    Congrats to for setting the Guinness World Record for largest business partnering event!

  123.   Retweeted

    Diversity and inclusion in science goes beyond who’s at the bench and all the way to who the science serves – 80% of NIH’s genomic data that’s used to push forward precision medicine is from people of European descent. (That’s not okay)

  124.   Retweeted

    speed networking is happening now! Booth #2001

  125.   Retweeted

    Honored to have had the opportunity to address this morning and talk about how real, palpable ultimately means real, palpable patient impact!

  126.   Retweeted

    We don’t do germline editing; society is not at a place to be ready for this, also it’s against recs, says Sandy Macrae . Carrie Wolinetz agrees, says term distinction is crucial, confusing these can feed back into regulatory framework detrimentally.

  127.   Retweeted

    What question would you ask at a discussion about the regulatory framework in human genome editing?

  128.   Retweeted

    “One patient at a time, positive responses are demonstrating that RNAi technology indeed has the potential to bring about a paradigm shift in medicine,” writes Mano Manoharan, SVP, Innovation Chemistry, in a blog post discussing our journey to advance therapeutics.

  129.   Retweeted

    The opportunities to advance the clinical trial model with personalized and targeted approaches are endless, from in the

  130.   Retweeted

    Fantastic dialogue going on in 204AB at . Completely candid remarks from tremendous group

  131.   Retweeted

    It was great to meet Jim Greenwood, CEO of at . – Robert Naismith, Chairman

  132.   Retweeted

    Wow knows how to put a stellar diverse panel together 🙌

  133.   Retweeted

    Front and center, Maryland is in a prime position to move business and innovation forward!

  134.   Retweeted

    This is a loaded panel & plenty of seats avail. Turbo charge R&D activities in 252AB

  135.   Retweeted

    Q to panel as public co CEOs – how do you investor risk? Dahiyat says people will invest if they think co. will make money either way. Hastings says will push some away, draw others in, so do what’s right.

  136.   Retweeted

    Our Biocom team has been taking full advantage of making ALL the connections at ! Check us out at the California Pavilion or stop by Startup Stadium tomorrow where we’ll be supporting our member !

  137.   Retweeted

    For those interested in learning more about gene-based therapies, make sure to attend the “Making Genetic Therapies a Reality for Patients” panel featuring our Chief Commercial Officer, Emmanuel Dulac.

  138.   Retweeted

    & Dx Track” has showed progress on several policy fronts. But , , reps say providers are still not incentivized to deliver holistic, value-based medicine. Reimbursement paradigms must evolve, they say.

  139.   Retweeted

    Travis McCready from closes out the Possible Talks at in the – “The only way that this industry will evolve, the only way we’ll find cures, is to develop the next generation of diverse talent and to break the mold.” That’s a wrap!

  140.   Retweeted

    “Breakthrough cience occurs when you cross disciplines” Mikael Dolsten

  141.   Retweeted

    🛑! Working on a slide deck to communicate your awesome 🔬? Here are some presentation basic design tips 🎨 for this week’s !

  142.   Retweeted

    Representatives from European biotech, regulatory and venture capital describe the state of investments in Europe and how global participants can get involved

  143.   Retweeted

    Great to meet Australia’s top medical entrepreneurs, discussing how they can take their successful ideas global, creating more jobs and improving patient outcomes

  144.   Retweeted

    Biologos is having a great time at this week in Boston!

  145.   Retweeted

    Great panel at on Digiral Medicines with leaders of of of Marisa Cruz of and Mostafa Kamal of Magellan

  146.   Retweeted

    Great points from re patient consent, consent for life, by Sandy Macrae, and need to ensure patients truly understand what it is they are committing to

  147.   Retweeted

    Q based on diversity training: anybody willing to do training similar to Starbucks? Dahiyat says his company already diverse, but reaches out to area to encourage diversity in science. Johnson says similar program at Dare – get more diversity in science with local youth.

  148.   Retweeted

    Over a 7-year period biotech job growth outpaced national growth by 14% Visit to find out why call home

  149.   Retweeted

    Life sciences companies aren’t innovating processes with and other technologies, but whoever tackles this first will win. from leads a discussion at with leaders from , , , and .

  150.   Retweeted
  151.   Retweeted

    Independent test results confirm the new VIP ECO upright ultra-low temperature freezer has the lowest total daily energy usage in its class in the industry. Visit us at this week Booth 1927 to learn more. Download your white paper here:

  152.   Retweeted

    DrugDeliveryExperts Retweeted BIO Intl Convention

    And DDE was there… Congrats to !

    DrugDeliveryExperts added,

  153.   Retweeted

    Save the date… reminding everyone at to come visit us next year in !

  154.   Retweeted

    Some impressions representing trends on : , driving the funnel and from all over the world – at Boston Convention & Exhibition Center

  155.   Retweeted

    “Europe is a uniquely attractive place for biotech”; lively discussion at our session on Europe’s value proposition for + investment

  156.   Retweeted

    Dahiyat continues: If you are running your business in a way that is profitable, investors won’t care. If not, it doesn’t matter if you’re silent anyway.

  157.   Retweeted

    Thank you for joining today’s panel with and the and for working with us to bring the patient viewpoint forward in value assessment.

  158.   Retweeted

    Now on stage at former MA governor ; extremely inspiring and a good example that a strong political vision is a key to Life Sciences Cluster development

  159.   Retweeted

    Hats off to — Been coming for most of the last 15 years, and I’ve never seen this level of buzz about business, doing things, in . Congrats on a job well done.

  160.   Retweeted

    Today Paul Stoffels, CSO of will be discussing new strategies for the development of & for the developing world. If you’re at head to Room 251, Level 2 at 3:00pm.

  161.   Retweeted

    Fireside Chat speaker and BIO Board of Directors chair on diversity and business

  162.   Retweeted

    THE is performing LIVE at TONIGHT at the BCEC! You must have a Convention Access badge to enter, and warning: space is extremely limited. Admittance is first-come, first-served, so make sure to arrive early! Thanks to our sponsors

  163.   Retweeted

    WIB Pittsburgh Retweeted Women In Bio

    For those of you at , check this out!

    WIB Pittsburgh added,

  164.   Retweeted

    Mark your calendars! Chief Scientific Officer Paul Stoffels will sit down with founder on Monday at 4pm at to discuss how we can speed innovation in science and medicine.

  165.   Retweeted

    I believe in dreaming big and focusing small ~ great words to live by. BIOConvention

  166.   Retweeted

    So much going on today at ! Keynotes from industry leaders, panels on cutting edge research, and 1×1 partnering now happening in the Business Forum!

  167.   Retweeted

    To all who will be attending this week, a very warm welcome to my adopted hometown…AKA “The City of Champions” (in case you’ve forgotten!).

  168.   Retweeted